Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... [Yahoo! Finance]
Taysha Gene Therapies, Inc. (TSHA)
Company Research
Source: Yahoo! Finance
General and Administrative Expenses: $33.9 million for the year ended December 31, 2025, compared to $29 million in 2024. Net Loss: $109 million or $0.34 per share for the year ended December 31, 2025, compared to $89.3 million or $0.36 per share in 2024. Cash and Cash Equivalents: $319.8 million as of December 31, 2025. Additional Funding: $50 million raised in gross proceeds through an at-the-market equity offering program in the fourth quarter. Cash Runway: Expected to fund operations into 2028. Warning! GuruFocus has detected 3 Warning Sign with TSHA. Is TSHA fairly valued? Test your thesis with our free DCF calculator. Release Date: March 19, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points Taysha Gene Therapies Inc ( NASDAQ:TSHA ) announced compelling Phase I/II data for TSHA-102, showing a 100% response rate in patients with Rett syndrome. The company received FDA breakthrough therapy
Show less
Read more
Impact Snapshot
Event Time:
TSHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSHA alerts
High impacting Taysha Gene Therapies, Inc. news events
Weekly update
A roundup of the hottest topics
TSHA
News
- How FDA Breakthrough Status For TSHA-102 At Taysha Gene Therapies (TSHA) Has Changed Its Investment Story [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies (TSHA) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TSHA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "seMarketBeat
- Taysha Gene Therapies (TSHA) had its price target raised by Needham & Company LLC from $10.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
- Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies (TSHA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $12.00 price target on the stock.MarketBeat
TSHA
Earnings
- 3/19/26 - Miss
TSHA
Sec Filings
- 3/19/26 - Form 10-K
- 3/19/26 - Form 8-K
- 2/27/26 - Form 144
- TSHA's page on the SEC website